TY  - JOUR
AU  - Llombart-Cussac, Antonio
AU  - Pérez-García, José Manuel
AU  - Bellet, Meritxell
AU  - Dalenc, Florence
AU  - Gil-Gil, Miguel
AU  - Ruíz-Borrego, Manuel
AU  - Gavilá, Joaquín
AU  - Sampayo-Cordero, Miguel
AU  - Aguirre, Elena
AU  - Schmid, Peter
AU  - Marmé, Frederik
AU  - Di Cosimo, Serena
AU  - Gligorov, Joseph
AU  - Schneeweiss, Andreas
AU  - Albanell, Joan
AU  - Zamora, Pilar
AU  - Wheatley, Duncan
AU  - Martínez-de Dueñas, Eduardo
AU  - Amillano, Kepa
AU  - Malfettone, Andrea
AU  - Cortés, Javier
AU  - PARSIFAL Steering Committee and Trial Investigators
PY  - 2021
DO  - 10.1001/jamaoncol.2021.4301
UR  - https://hdl.handle.net/10668/27202
T2  - JAMA oncology
AB  - The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer. Meanwhile, the...
LA  - en
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Breast Neoplasms
KW  - Female
KW  - Fulvestrant
KW  - Humans
KW  - Letrozole
KW  - Middle Aged
KW  - Piperazines
KW  - Pyridines
KW  - Receptor, ErbB-2
TI  - Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.
TY  - research article
VL  - 7
ER  -